Changes in Hong Kong stocks | The CRO concept had the highest increase, Pharma Ming (02359) received a preliminary injunction from the US court to suspend execution of the Department of Defense's 1260H certification

The Zhitong Finance App learned that the CRO concept had the highest increase. As of press release, Kingsley Biotech (01548) rose 6.44% to HK$24.46; Pharmaceutical Kangde (02359) rose 5.36% to HK$202.8; Pharmaceutical Biotech (02269) rose 5.02% to HK$48.16; and Kanglong Chemical (03759) rose 4.15% to HK$28.62.

According to the news, Yao Ming Kant issued an announcement. The US District Court for the District of Columbia approved the company's preliminary injunction motion on August 7. While the company is being sued for inclusion in the 1260H list, the US Department of Defense is prohibited from enforcing the relevant findings or taking any other action based on it. The company said the ruling protected the company from the immediate adverse effects of the 1260H determination during the lawsuit against the US Department of Defense.

At the performance level, the semi-annual report results disclosed by a number of leading CRO companies greatly exceeded expectations. Yao Ming Kangde achieved operating income of 28.897 billion yuan in the first half of 2026, an increase of 38.93% year on year, and net profit attributable to shareholders of listed companies was 11.08 billion yuan, up 29.43% year on year. The company comprehensively raised the 2026 annual performance guidelines to raise the year-on-year growth rate of continuing business revenue from 18%-22% to 35%-39%; Kanglong Huacheng's new orders increased by more than 30% year on year; Gloria Ying Q1's order amount increased by 127.59 percent year on year %, of which overseas orders accounted for 58.42%.